Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice - Wikidata - wikimedia - TriplyDB

Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice

Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice

http://www.wikidata.org/entity/Q36745089

about

Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2 Recombinant tissue plasminogen activator enhances microglial cell recruitment after stroke in mice Neutrophil migration towards C5a and CXCL8 is prevented by non-steroidal anti-inflammatory drugs via inhibition of different pathways Role of Neutrophils in Exacerbation of Brain Injury After Focal Cerebral Ischemia in Hyperlipidemic Mice Targeting neutrophils in ischemic stroke: translational insights from experimental studies.Chemokines and neurodegeneration in the early stage of experimental ischemic stroke.Regulation of atherosclerotic plaque inflammation.Ticks from diverse genera encode chemokine-inhibitory evasin proteins.Endothelial cell dysfunction as a novel therapeutic target in atherosclerosis.The CXCR2 Gene Polymorphism Is Associated with Stroke in Patients with Essential Hypertension.Evasin-displaying lactic acid bacteria bind different chemokines and neutralize CXCL8 production in Caco-2 cells.Treatment with Evasin-3 abrogates neutrophil-mediated inflammation in mouse acute pancreatitis.Alamandine abrogates neutrophil degranulation in atherosclerotic mice.The role of monocytosis and neutrophilia in atherosclerosis.Update on the effects of treatment with recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke.Genetic deletion of the adaptor protein p66Shc increases susceptibility to short-term ischaemic myocardial injury via intracellular salvage pathways.Immunological aspects of atherosclerosis

P2860

Q27005956-83F20605-EBDC-47F9-8D10-AB4197FC8C85 Q33581243-28418AAA-541B-48CB-AF79-002DE743E7F2 Q33929754-871F89F6-D751-45F0-A18C-B81F9F614BE3 Q36109158-06134B75-2A08-4DCD-BD06-32B908553BF8 Q36267227-73E36942-89F5-4A38-BA8C-9C44F954FA70 Q37351594-2BC7EC06-F064-4C9D-A587-91A3F025CC31 Q38396097-A7024355-AA85-46C3-961A-A3E9FC629C3E Q38646647-F35F9E68-73DE-4CAE-929E-1BDBFA1DC04A Q38881790-8B97DA2A-FAB1-4819-A60D-D9A4A1C87D5B Q41065383-FCBEA9F5-AA96-4BE9-AA2F-3EEB9AB0C6A7 Q43216438-CEAF2E48-54AD-4AF8-98A3-D5EECBA05896 Q46851060-A573214B-96C3-4E87-9E33-A498232EA08C Q47847982-F9DF292A-E783-49E4-A270-EFBD3F2AE450 Q48175299-024798D4-3A2E-448A-91BF-6C289F102B3C Q48558308-2591EDF5-F89A-4985-969E-419B612C58EA Q54314174-98F75F5E-ADC1-4CD5-A8A1-F01DF92F878E Q58197587-32CA3613-93A4-43E9-B65E-F98A2139C685

P2860

Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice

http://www.wikidata.org/entity/Q36745089

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Treatment with Evasin-3 reduce ...... , but not brain injury in mice

@ast

Treatment with Evasin-3 reduce ...... , but not brain injury in mice

@en

type

label

Treatment with Evasin-3 reduce ...... , but not brain injury in mice

@ast

Treatment with Evasin-3 reduce ...... , but not brain injury in mice

@en

prefLabel

Treatment with Evasin-3 reduce ...... , but not brain injury in mice

@ast

Treatment with Evasin-3 reduce ...... , but not brain injury in mice

@en

P1433

Q36745089-49C5DC6D-24D5-4EDD-881E-ED23A98964F9

P1476

Q36745089-15072239-BC29-435C-A270-A2D758F098E1

P2093

Q36745089-07159FE1-FE90-43B3-B974-11BF95D64E01

Q36745089-1D50F17E-3544-4D48-9B93-CB3D13637A1A

Q36745089-47B5C00A-00B5-4485-93CD-A1C15927B29E

Q36745089-55F616D4-59EC-44CA-B22A-1C081C5900D5

Q36745089-60D6BAFF-35C5-4586-A74E-D143EA7D5618

Q36745089-6E362305-B4D3-4B49-A9A4-A15EFD521331

Q36745089-81EF668B-B014-4B5B-AA29-69FC3F56324E

Q36745089-8BCEF43B-6775-4D00-BE84-4AE5AAE34F8B

Q36745089-A12A5C1F-0008-409B-AFA4-FC8B3B07F2E5

Q36745089-C319B2B5-A3E4-44A8-925E-92997AA9841C

P2860

Q36745089-0127DFAC-AC71-4E65-A9F2-49615EE7A7F7

Q36745089-08AB211B-73DD-4954-8153-30876886882D

Q36745089-0DE88FF4-0244-4FDF-B712-AFC049A905AA

Q36745089-0E4D7C18-717E-4A2E-95A7-24BED36794EA

Q36745089-0F2ACFCA-4790-4719-A0E9-BADA855E942C

Q36745089-11B5AD34-FE7A-492D-BF79-76CF1DBCCDF0

Q36745089-1F789A75-D15D-46E5-9D3C-BE70852E9053

Q36745089-2D50EA8D-D3FC-48D4-A0D0-7CF6862B6037

Q36745089-3771AA7F-73E9-4B32-B8E8-A954F508305E

Q36745089-37E7EF86-D0AF-4C6E-AB67-37DF84508B79

P304

Q36745089-32F5950D-AA4A-4071-B5DD-BF18D8B340AC

P31

Q36745089-3FB6258A-B4DD-494D-89F9-339118DF2C89

P356

Q36745089-FFD5EE30-5A3E-4605-B975-5F19C4329468

P433

Q36745089-000373F0-AAED-4E35-B2A0-7240766CECF5

P478

Q36745089-50279F0F-7A93-44A9-9F5B-6270818FD783

P50

Q36745089-0FC9C3CF-AB31-4177-A6A5-5902EC6A93B9

Q36745089-26A41213-A784-40DB-92B2-F230CA552D5F

Q36745089-4DBEEBD5-C930-4705-A24A-EC70EF3D8130

Q36745089-53B1F7F2-1875-4442-98BB-0E0F9EF429F8

Q36745089-CACB51F1-8795-4D76-94C3-6319F488872C

Q36745089-ECD353E7-4C85-4B90-A070-A7612F89F743

P577

Q36745089-91833073-9172-46FD-9922-5F610A8C1118

P5875

Q36745089-F13568FB-C88C-4475-BF9D-DDA7D3E5ED0A

P698

Q36745089-36BA5C3F-AAB2-4F55-B5B1-FC0BAC09AA0A

P921

Q36745089-6A1CD1C8-DA45-4546-B54D-896B0911FF64

P932

Q36745089-13A70A31-142A-4205-A32D-5E166187FF31

P356

P1433

Journal of Cerebral Blood Flow & Metabolism

P1476

Treatment with Evasin-3 reduce ...... , but not brain injury in mice

@en

P2093

Amanda E Proudfoot

http://www.w3.org/2001/XMLSchema#string

François Mach

http://www.w3.org/2001/XMLSchema#string

Graziano Pelli

http://www.w3.org/2001/XMLSchema#string

Jean-Christophe Copin

http://www.w3.org/2001/XMLSchema#string

Karl Schaller

http://www.w3.org/2001/XMLSchema#string

Katia Galan

http://www.w3.org/2001/XMLSchema#string

Maud Deruaz

http://www.w3.org/2001/XMLSchema#string

Nikolaos Stergiopulos

http://www.w3.org/2001/XMLSchema#string

Robson A S Santos

http://www.w3.org/2001/XMLSchema#string

Rodrigo A Fraga-Silva

http://www.w3.org/2001/XMLSchema#string

P2860

Projections of global mortality and burden of disease from 2002 to 2030

Inflammation, atherosclerosis, and stroke.

Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization.

A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging.

MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke.

Role of Rac1 GTPase in NADPH oxidase activation and cognitive impairment following cerebral ischemia in the rat

Chemokine-related gene expression in the brain following ischemic stroke: no role for CXCR2 in outcome.

Shear stress-induced changes in atherosclerotic plaque composition are modulated by chemokines.

The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques.

The therapeutic potential of CXC chemokine blockade in acute inflammation in the brain.

P304

490-498

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/JCBFM.2012.198

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Fabrizio Montecucco

Rafaela Fernandes da Silva

Franco Dallegri

Luciano Capettini

Fabienne Burger

Vincent Braunersreuther

P577

2012-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233948809

http://www.w3.org/2001/XMLSchema#string

P698

23250107

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

3618389

http://www.w3.org/2001/XMLSchema#string